Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents
Abstract
SVR12 rates for sofosbuvir-based DAA regimens in HCV-MCS were 83%, significantly higher than historical controls treated with pegylated interferon and ribavirin; patients with glomerulonephritis experienced improvement in renal function, including those not concomitantly treated with immunosuppressi …
Keywords
hepatitis c
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
research support
non-u.s. gov't
adult
female
male
N.I.H.
Extramural
aged
middle aged
Retrospective Studies
antiviral agents / therapeutic use*
ribavirin / therapeutic use*
chronic / drug therapy*
interferon-alpha / therapeutic use*
clinical study
chronic / complications*
sofosbuvir / therapeutic use*
pmid:26474537
pmc4718772
doi:10.1002/hep.28297
meghan e sise
allyson k bloom
raymond t chung
cryoglobulinemia / drug therapy*
cryoglobulinemia / virology*
Access
Citation
ID:
272363
References
Blockchain Verification
Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
272363
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
Creates 1,000,000 NFT tokens for this article
Token Features:
- ERC-1155 Standard NFT
- 1 Million Supply per Article
- Transferable via MetaMask
- Permanent Blockchain Record
Scan with Saymatik Web3.0 Wallet